drugset / Trial / NCT00981318

Pilot Assessment of Lopinavir/Ritonavir and Maraviroc

NCT00981318

Phase 4 Terminated 3 enrolled Rodwick, Barry M., M.D. Abbott · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a study to assess the response of lopinavir/ritonavir plus maraviroc (with no nucleoside medications) in HIV patients failing their initial antiviral therapy.

Timeline

Start
2009-12
Primary completion
2015-05
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Lopinavir Other / unclassified 400 mg
Subject Maraviroc Other / unclassified 150 mg
Subject Ritonavir Other / unclassified 100 mg

Indications